Group a streptococcal m-related proteins and methods of use
AssigneeUniversity of Tennessee Research Foundation
InventorsJames B. Dale, Harry S. Courtney
Life of this patent
Estimating the term…
Abstract
Immunogenic group A streptococcus M-related polypeptides and peptides and immunogenic compositions comprising these M-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-GAS and anti-SDSE antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise M-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group A streptococcus immunogen, such as an M peptide or Spa peptide.
Claims45
An isolated polypeptide selected from:
- (a) an isolated polypeptide consisting of an amino acid sequence at least 70% identical to the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- (b) an isolated polypeptide consisting of an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- (c) an isolated polypeptide consisting of an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- (d) an isolated polypeptide consisting of an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- (e) an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- (f) an isolated polypeptide comprising an immunogenic fragment that comprises at least 15 contiguous amino acids of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55;
- and
- (g) an isolated polypeptide that is a variant of a polypeptide consisting of the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55, wherein the variant has no more than 10 amino acid additions, deletions, or substitutions in the amino acid sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:39, SEQ ID NO:47;
- or SEQ ID NO:55,
- wherein the isolated polypeptide evokes an immune response specific for group A streptococcus (GAS).
-30. (canceled)
-35. (canceled)
(canceled)
-45. (canceled)
A method for inducing an immune response in a subject against Streptococcus dysgalactiae subspecies equisimilus (SDSE) with an immunogenic composition comprising a pharmaceutically acceptable excipient and an immunogenic peptide comprising at least 25 contiguous amino acids from the amino terminal portion of a group A streptococcus (GAS) serotype M protein or a Spa protein.
A method for treating or preventing a Streptococcus dysgalactiae subspecies equisimilus (SDSE) infection in a subject, comprising administering an immunogenic composition comprising a pharmaceutically acceptable excipient and an immunogenic peptide comprising at least 25 contiguous amino acids from the amino terminal portion of a group A streptococcus (GAS) serotype M protein or a Spa protein.
A method for reducing the likelihood of occurrence of a Streptococcus dysgalactiae subspecies equisimilus (SDSE) infection in a subject, comprising administering to the subject an immunogenic composition comprising and an immunogenic peptide comprising at least 25 contiguous amino acids from the amino terminal portion of a group A streptococcus (GAS) serotype M protein or a Spa protein.
-70. (canceled)
Dependencies are inferred from the claim text.